This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach.
City: Barcelona (Spain)
Financial Data: €81.50M Market Cap (Bolsa de Madrid)
CEO: Carlos Buesa
Mission: Oryzon is a clinical-stage biopharma and a European leader in epigenetics-based therapeutics. In the beginning of its operations (2000-2008), Oryzon focused on genomics diagnostics. In 2008, it acquired Crystax Pharmaceuticals and started its own drug discovery programs.
Building on its platforms in genomics and epigenomics, Oryzon is able to identify biomarkers that can be translated into new therapeutic targets. Specifically, it focused on the development of small molecules for oncology and neurodegenerative diseases.
Its candidates target lysine-specific demethylase 1 (LSD1/KDM1A),